Table 5. Identification rate of SLN-CEUS and subgroup analysis.
| Patients | Detected (n) | Undetected (n) | Identified rate |
|---|---|---|---|
| Overall | 308 | 19 | 94.2% (308/327) |
| Subgroup | |||
| Non-NAT | 210 | 8 | 96.3% (210/218) |
| NAT | 98 | 11 | 89.9% (98/109) |
| P value* | 0.037 | ||
| Subgroup | |||
| Surgery history† | 36 | 1 | 97.3% (36/37) |
| No surgery history | 272 | 18 | 93.8% (272/290) |
| P value* | 0.708 |
*, P values are from the chi-square test or Fisher exact test, as appropriate; †Surgery history includes ipsilateral breast or axillary surgery history. Fine needle aspiration biopsy is not included. SLN-CEUS, contrast-enhanced ultrasound of sentinel lymph node; NAT, neoadjuvant treatment.